Company ProfilePremium

Niki BioSolutions Inc.

Company Profile Analysis

Ticker: NIKI

ESOMAR 23 Corporate BadgeISO Certifications Badge
Niki BioSolutions Inc. - Company showcase

Year Founded & Workforce

2010

1 Employees

Niki BioSolutions Inc. logo

Niki BioSolutions Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Niki BioSolutions Inc. Overview

Niki BioSolutions is a sub-$20M market-capitalization life-sciences company built from two components. The first is a dormant Hong Kong-rooted drug developer, legacy Aptorum. The second is DiamiR Biosciences, a small Princeton, New Jersey molecular-diagnostics company. The combined company describes itself as a clinical-stage life-sciences business that provides genomic and biomarker testing through a CLIA-certified, CAP-accredited laboratory, with a focus on brain health and oncology. Its strategic center of gravity is now DiamiR's proprietary plasma microRNA platform for early detection and monitoring of mild cognitive impairment, Alzheimer's, Parkinson's and cancer, plus a New York State-approved APOE genotyping test sold as a laboratory service. The legacy therapeutics, SACT-1 (neuroblastoma) and ALS-4 (anti-virulence for MRSA), have completed Phase 1 but are suspended until partners and funding are found. The company has no product revenue, carries going-concern doubt, depends on a $75M shelf, and is controlled by insiders. It is a high-risk, early-stage option on blood-based neurodegeneration diagnostics.


Company's own description (paraphrased from latest filings)

The September 18, 2026 Form S-3/A is the most recent comprehensive company description. It describes Niki as a clinical-stage life-sciences company that addresses unmet medical needs and provides genomic and biomarker testing to healthcare providers, research institutions and life-sciences organizations through its CLIA-certified, CAP-accredited laboratory. It says the company pairs proprietary technologies with scientific rigor to support precision medicine in brain health and oncology, and that it collaborates with academic centers, disease foundations and biopharma companies.

Legacy Aptorum's FY2025 Form 20-F (filed March 27, 2026) described a clinical-stage biopharmaceutical holding company. Its stated work was discovering, developing and commercializing therapeutic assets and diagnostic technologies, mainly in oncology (including orphan oncology indications) and infectious disease. Its lead projects were ALS-4 and SACT-1, with the PathsDxTest pathogen-identification platform co-developed with A*STAR's commercialization arm.

The S-3/A describes DiamiR as a molecular-diagnostics business. It is developing minimally invasive tests for early detection and monitoring of mild cognitive impairment (MCI), Alzheimer's, Parkinson's, other neurodegenerative diseases and cancer. The tests rest on quantitative analysis of circulating organ-enriched microRNAs (miRNAs) in plasma. The near-term objective is to launch laboratory-developed tests (LDTs) in DiamiR's CLIA-licensed laboratory, which could support patient screening and stratification as well as disease and treatment monitoring.

Independent characterization

LayerWhat it isEconomic status (Oct 2026)
Diagnostics services (DiamiR)CLIA/CAP laboratory offering APOE genotyping and biomarker testing services to research sponsors and clinical research sitesSmall, early revenue potential. DiamiR "has received revenue in the past" from testing services to life-sciences companies, but amounts are not publicly disclosed in sources reviewed
Diagnostics pipeline (DiamiR)Plasma microRNA signatures for MCI/AD, Parkinson's, glioblastoma and other indications; planned LDTsPre-commercial; no product revenue
Therapeutics (legacy Aptorum)SACT-1 (repurposed, neuroblastoma; orphan drug designation; 505(b)(2) pathway agreed with FDA); ALS-4 (anti-virulence small molecule, S. aureus/MRSA); preclinical follow-onsPhase 1 completed (2022). R&D suspended since the YOOV deal collapsed in late 2024. Phase 2 contingent on partners/funding
Investments$15.1M long-term investments carried at Dec 31, 2025 (composition not detailed in sources reviewed); Libra Sciences VIE (97.27% economic interest, not consolidated)Non-cash, illiquid; drives most of book equity
Customer typeExample / evidenceEnd-market
Clinical research organizations / sitesProgressive Medical Research (APOE genotyping services agreement, Jul 23, 2026)Alzheimer's clinical trials and translational research
Diagnostics/platform companiesInstant NanoBiosensors (validation of G8 APOE analyzer, Feb 2, 2026); AlzLabs Precision Diagnostics (biomarker data collaboration, Jun 22, 2026)Blood-based brain-health testing
Academic centersUniversity of Pennsylvania (glioblastoma miRNA study, Mar 2026)Neuro-oncology research
BiopharmaHistorical testing services to life-sciences companies (S-3/A)Drug development support
Grantors / foundationsDiamiR historically funded by government agencies and a private foundation (S-3/A)Non-dilutive research funding
(Legacy) Hong Kong outpatientsAML Clinic / Talem MedicalPrimary care services (discontinued)

Niki is best understood as a holding company in transition with three economically distinct layers.

Business model and revenue mix. Legacy Aptorum's only revenue ever recorded came from healthcare services: an outpatient clinic in Hong Kong, the AML Clinic, operated as Talem Medical. That revenue was $1.54M in FY2021, $1.30M in FY2022 and $0.43M in FY2023, and nil in FY2024–FY2025 (FY2022 and FY2025 Form 20-F). Prospectively, the model is fee-for-service laboratory testing: APOE genotyping and biomarker panels for research sponsors and clinicians. Over time the company hopes to add higher-value proprietary LDTs and potential licensing or partnering income on the therapeutics. There is no subscription or product-sales revenue.

Value-chain position. In diagnostics, Niki sits at the assay-development and reference-laboratory stage. It runs tests in-house and validates third-party platforms, such as Instant NanoBiosensors' G8 analyzer. It does not manufacture in-vitro diagnostic kits. In therapeutics it is a virtual developer that relies on CROs (for example, Covar Pharmaceuticals) and licensors.

Customer types and end-markets.

Strategy

Stated strategy themes (paraphrased)

  1. Pivot to precision diagnostics for brain health. Make DiamiR's plasma miRNA technology and CLIA/CAP lab the core of the business. Launch LDTs and use them for screening, stratification and monitoring in neurodegeneration (S-3/A, 2026).

  2. Build a testing-services revenue base. Expand validated service offerings (APOE genotyping, protein biomarker panels) and lab throughput, including the automated INB platform validation (Feb 2026), the PMR services agreement (Jul 2026) and the AlzLabs data collaboration (Jun 2026).

  3. Partner the legacy therapeutics. Advance ALS-4 to Phase 2 and SACT-1 to Phase 1/2 only with strategic collaborators who bring both money and clinical expertise (FY2025 20-F; S-3/A).

  4. Collaborate with academia, foundations and biopharma to generate clinical validation and non-dilutive funding (S-3/A).

  5. Normalize the corporate platform for U.S. capital markets. Delaware domestication, domestic SEC reporting, a $75M shelf, and investor-conference visibility (H.C. Wainwright, Sep 14, 2026; Lytham Partners, Sep 29–30, 2026).

Initiative register (last 24 months)

DateInitiativeTypeDetail
Jul 14, 2025DiamiR merger agreement plus Management Services Agreement and IP LicenseTransformation / M&AThe MSA and license gave Aptorum Therapeutics non-exclusive access to DiamiR IP for upfront and periodic payments and royalties until close. Both terminated at closing
Aug 21, 2025NYS approval of the APOE genotyping testProduct/regulatoryEnables testing of New York specimens
Oct 10, 2025Up to $6M RDO with warrantsFinancing$2M upfront plus up to $4M on warrant exercise at $2.00 (pre-split)
Nov 19, 2025Two CTAD 2025 abstractsScientific validationAlzheimer's clinical-trials conference
Feb 2, 2026INB APOE platform validationPartnership / capacityAutomation of APOE testing
Mar 10, 2026UPenn glioblastoma miRNA publicationScientific validationExtends the platform to neuro-oncology
Jun 22, 2026AlzLabs biomarker collaborationPartnershipProtein plus miRNA data on amyloid-PET-characterized samples
Jul 2026Three AAIC 2026 presentationsScientific validationAlzheimer's Association International Conference
Jul 20, 20262026 Incentive PlanTalent/compensationEquity plan for the combined company
Jul 23, 2026PMR APOE testing services agreementCommercialFirst post-merger commercial agreement announced
Aug 28, 2026$75M universal shelf (S-3)FinancingBaby-shelf limits apply; see Section 21
Sep 2026Investor conference programCapital marketsH.C. Wainwright (Sep 14); Lytham Partners (Sep 29–30)

Sustainability/ESG commitments: none disclosed.

Cost programs: none announced formally. A de facto cost program (R&D suspension, headcount reduced to one) ran in 2023–2025.

Medium-term targets / guidance

The company has issued no quantitative revenue, margin, cash-runway or test-volume guidance in sources reviewed.

Products & Services

Diagnostics & laboratory services (DiamiR Biosciences)

OfferingDescription & capabilitiesTarget customerStatus / yearPricing model
Plasma microRNA platform (proprietary)Quantitative analysis of circulating organ-enriched miRNAs in plasma, intended for minimally invasive detection and monitoring of MCI, Alzheimer's, Parkinson's, other neurodegenerative diseases and cancer. Planned uses are screening, patient stratification and monitoring of disease and treatmentNeurologists, clinical-trial sponsors (enrichment/stratification), research institutionsPre-commercial. LDTs planned in the CLIA lab (S-3/A, 2026)—
APOE genotyping testIdentifies the ε2/ε3/ε4 alleles. ε4 is the strongest known genetic risk factor for late-onset Alzheimer's. Run in DiamiR's CLIA-certified, CAP-accredited labClinical research sites, sponsors, cliniciansNew York State approval announced Aug 21, 2025. Services agreement with Progressive Medical Research, Jul 23, 2026Fee-for-service; specific prices not disclosed
Automated APOE testing validation (with INB)DiamiR compares Instant NanoBiosensors' automated G8 Genotyping Analyzer against its NYS-approved APOE test. Management expects higher testing capacity and lab throughputInternal capacity; potential service expansionCollaboration announced Feb 2, 2026; validation status not reported—
Neurodegeneration biomarker data generation (with AlzLabs)Measures protein biomarkers (p-Tau217, Aβ42/40, NfL and others) and miRNA in plasma samples with amyloid-PET-confirmed statusDiagnostic developers; future clinical panelsCollaboration announced Jun 22, 2026—
Glioblastoma miRNA biomarker researchmiRNA biomarker study with the University of Pennsylvania, published in the journal DiagnosticsNeuro-oncology researchPublication announced Mar 10, 2026—
Contract testing servicesTesting services for life-sciences companiesBiopharmaHistorical; revenue amounts not disclosed (S-3/A)—
Scientific presentationsTwo abstracts at CTAD 2025 (Nov 2025); three presentations at AAIC 2026 (Jul 2026)Scientific community2025–2026—

Therapeutics (legacy Aptorum)

AssetModality / mechanismIndicationDevelopment statusRegulatory notes
SACT-1Repurposed small-molecule drugNeuroblastoma (pediatric); potentially other cancersPhase 1 completed with positive results (2022); End-of-Phase-1 meeting with FDA completed. Phase 1/2 contingent on partnership and fundingFDA Orphan Drug Designation; FDA agreed to a 505(b)(2) pathway for a pediatric formulation (FY2025 20-F risk factors)
ALS-4First-in-class anti-virulence small moleculeS. aureus infections including MRSA. Aggregators also list M. tuberculosis and P. aeruginosaPhase 1 completed with positive results (2022). Phase 2 contingent on partners and fundingPre-IND discussions with FDA (2023)
SACT-COV19Repurposed small moleculeCOVID-19Preclinical (aggregator description; likely inactive)—
SACT-2, SACT-3Repurposed candidatesOncologyPreclinical (aggregator description)—
ALS-1Small moleculeS. aureus/MRSA infectionsPreclinical (aggregator description)—
ALS-2/3Small moleculesGram-positive bacterial infectionsPreclinical (aggregator description)—
PathsDxTest (formerly RPIDD)Molecular, NGS-based rapid pathogen identification from liquid biopsyInfectious-disease diagnosticsClinical validation studies reported in 2022; co-developed with Accelerate Technologies Pte Ltd (A*STAR commercialization arm). Current status not disclosed—

Important context. R&D was paused during the YOOV process and remained suspended after its termination (H1 2024 results release, Dec 2024). R&D spending fell from $10.87M in FY2021 to $0.35M in FY2025 (Form 20-F). The company has stated it is seeking strategic collaborators to provide financing and clinical expertise for ALS-4 Phase 2 and SACT-1 Phase 1/2 (FY2025 20-F; S-3/A).

Discontinued services

OfferingDescriptionStatus
AML Clinic (Talem Medical), Hong KongOutpatient medical clinic staffed by employed Hong Kong doctorsRevenue ceased after FY2023; operating entity struck off and dissolved (S-3/A)

Financial Narrative

Sources: FY2022 Form 20-F (FY2021–FY2022 data); FY2023 Form 20-F (FY2023 balance sheet and cash flows); FY2025 Form 20-F (FY2023–FY2025 income statement; FY2024–FY2025 balance sheet and cash flows). All figures are in USD thousands unless stated. Per-share data are on the January 2023 reverse-split basis as reported. A separate row restates them for the July 2026 1-for-10 consolidation.

Income statement

No income tax expense was recorded in any year, so pre-tax income equals net income. The July-2026-restated EPS row is an analyst restatement (× 10); the aggregator AlphaQuery shows −$1.90 for FY2025, consistent with this.

Items not publicly disclosed in sources reviewed: EBITDA (depreciation and amortization was not separated in the retrieved statements, so EBITDA and EBITDA margin cannot be computed without estimation). Revenue-based margins for FY2024–FY2025 are not meaningful because revenue was zero.

Margins (revenue-bearing years only):

Revenue CAGR: FY2021–FY2023 was −47.1% per year. A five-year CAGR is not meaningful because revenue fell to zero.

Commentary. The income statement shows a managed wind-down rather than an operating business. Operating losses fell 91% between FY2021 and FY2025, from $19.2M to $1.8M. The drivers were the suspension of R&D (CRO spend fell from $1.39M in FY2023 to $0.17M in FY2024 per the FY2024 20-F), the reversal of deferred bonuses (FY2023), and reduction of headcount to one employee.

Reported net results were repeatedly flattered by non-operating items. FY2022 included a $5.59M gain on long-term investments. FY2023 included a $6.43M unrealized fair-value gain, without which the FY2023 net loss would have been ~$10.8M rather than $4.3M. FY2025 included a $0.69M warrant-liability fair-value gain. Legal and professional fees exceeded R&D in FY2025 ($1.06M versus $0.35M), reflecting merger costs. That is a clear inflection: the company spent more on transaction work than on science.

Interim data. H1 2025 net loss was $449,295, against $2,658,887 in H1 2024 (Form 6-K interim, via TipRanks/Barchart). H1 2026 net loss was $1.31M, with no revenue and $1.55M operating cash burn (company filing, as reported by BriefGlance, Sep 8, 2026). The H1 2026 figures predate the merger close.

Balance sheet

How the debt rows are built: total debt is bank loans plus convertible notes plus loans from related parties, excluding leases. FY2022 is a $3.0M bank loan plus $3.01M convertible notes plus $0.5M related-party loan. FY2023–FY2025 are convertible notes payable to a related party ($3.06M → $3.24M → $3.42M). Net debt is total debt less unrestricted cash.

The FY2025 balance sheet also carries a $306K warrant liability and $47K contingently redeemable warrants in temporary equity, both from the October 2025 offering. These are excluded from debt.

Balance-sheet commentary. The single most important feature is the $15.1M long-term investment, which is 81% of FY2025 total assets. The underlying investee(s) and valuation method are not described in the sources reviewed. The balance grew from $4.2M (FY2021) to $16.1M (FY2023) largely through fair-value gains, then took a $1.0M impairment in FY2024. Because attributable equity of $23.1M is mostly this illiquid asset, tangible liquid equity is very thin.

Liquidity is weak. FY2025 working capital was −$1.0M, and cash of $3.45M sat against $4.59M of current liabilities, including $3.42M of convertible notes owed to a related party. By June 30, 2026, cash had fallen to $1.83M and working-capital deficit had widened to −$2.48M (BriefGlance citing filings).

Negative non-controlling interests (−$9.4M) reflect accumulated losses absorbed by minority holders of subsidiaries and VIEs.

Post-merger: DiamiR's balance sheet, any purchase-price allocation, goodwill or intangibles from the acquisition, and pro forma combined figures were filed on the Form 8-K/A (event Aug 21, 2026).

Cash flow

Notes. Capital expenditure is not separately disclosed in the sources reviewed, so free cash flow cannot be calculated precisely. AlphaQuery reports FY2025 FCF of −$1.84M, equal to OCF, which implies negligible capex.

The FY2025 20-F narrative table shows the FY2025 net change in cash in parentheses as a decrease of $2,578,653. The balance sheet shows cash rising from $874K to $3,453K, an increase of the same amount, so the parenthesis appears to be a presentation error.

The FY2023 financing inflow was made up of: $1.6M ATM proceeds, $2.5M related-party loans, and $3.0M convertible notes, less $3.0M bank-loan repayment (FY2023 results release). The FY2025 financing inflow came from the January 2025 RDO ($3.0M gross) and October 2025 RDO ($2.0M gross upfront).

Commentary. Cash burn fell from $14.7M (FY2021) to ~$1.2–1.8M (FY2024–FY2025). Even that reduced burn has not been funded internally: every year required equity or related-party financing. The large FY2021 investing inflow ($16.5M) reflects liquidation of marketable securities and repayments of related-party loans, not operations.

Ratios

Not meaningful or not disclosed: net debt/EBITDA (EBITDA negative and D&A not disclosed); interest coverage (operating income negative in all years); cash conversion cycle (no meaningful receivables, inventory or payables cycle after FY2023).

Trend synthesis. Return metrics "improve" only because the denominator stayed propped up by the carried investment while losses shrank. They do not reflect better operating economics. The decisive inflections were:

  • FY2022: liquidity crisis, with working capital of −$5.4M and a bank loan plus convertible notes.

  • FY2023: recapitalization through ATM, related-party loans and converts.

  • FY2024: near-dormancy.

  • FY2025: merger-driven re-financing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

MetricFY2021FY2022FY2023FY2024FY2025

Healthcare services revenue (USD K)

1,5421,29643100

Therapeutics revenue (USD K)

00000

Diagnostics revenue (USD K)

00000

Total revenue (USD K)

1,5421,29643100

Healthcare services share of revenue (%)

10010010000

Results by Segment

MetricFY2021FY2022FY2023FY2024FY2025

Healthcare services gross profit (USD K)

82801100

R&D expense, therapeutics and diagnostics (USD K)

10,8709,2205,1982,195353

Group operating loss (USD K)

-19,207-17,509-10,724-3,941-1,818

Segment Margins & Growth (%)

MetricFY2021FY2022FY2023

Healthcare services gross margin (%)

5.36.22.4

Healthcare services revenue YoY growth (%)

69.1-15.9-66.7

Group Entities

EntityRole / statusCumulative funding from parent (USD, through Sep 16, 2026)

DiamiR Biosciences Corp. (Delaware) and DiamiR, LLC

Operating diagnostics subsidiary; CLIA/CAP lab

—

Aptus Management Ltd

Group management/treasury

64,309,273

Aptorum Therapeutics Ltd

Therapeutics holding; counterparty to the DiamiR MSA and license

17,635,262

Acticule Life Sciences Ltd (80% owned)

ALS-series anti-infectives

5,218,255

Aptorum Medical Ltd (90% owned)

Former HK clinic (Talem Medical); struck off/dissolved

1,673,593

Aptorum Innovations Holding Pte (Singapore)

Diagnostics (PathsDx) holding

442,202

Claves Life Sciences Ltd

Struck off/dissolved

331,960

Signate Life Sciences Ltd

Struck off/dissolved

319,386

Scipio Life Sciences Ltd

Controlled since Nov 2024 (former VIE)

151,710

Aptorum Innovations Holding Ltd

Holding

15,087

Aptorum Pharmaceutical Dev. Ltd

Development

7,300

Aptorum Group LLC

U.S. entity

4,338

Libra Sciences Ltd (VIE)

97.27% economic interest / 31.51% voting; not consolidated

—

Nativus Life Sciences, Videns Incorporation

Wholly owned subsidiaries (20-F definitions)

—

Paths Diagnostics Pte. Ltd

PathsDxTest platform (per FY2024 filing summary)

—

“—” = not publicly disclosed.

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (USD K)

1,5421,29643100

Cost of healthcare services (USD K)

1,4601,21642100

Gross profit (USD K)

82801100

R&D expense (USD K)

10,8709,2205,1982,195353

General & administrative (USD K)

5,4095,2201,931669573

Legal & professional fees (USD K)

2,6182,8882,5388031,062

Other operating expense, net of income (USD K)

3932611,068273-171

Total operating expenses incl. cost of services (USD K)

20,74918,80511,1563,9411,818

Operating income (USD K)

-19,207-17,509-10,724-3,941-1,818

Total other income/(expense), net (USD K)

-7,9075,9846,383-217441

Pre-tax income (USD K)

-27,114-11,525-4,341-4,158-1,376

Net income, total (USD K)

-27,114-11,525-4,341-4,158-1,376

Net income attributable to company (USD K)

-25,048-9,800-2,825-4,268-1,363

EPS basic, as reported (USD)

-7.15-2.75-0.62-0.78-0.19

EPS diluted, as reported (USD)

-7.15-2.75-0.62-0.78-0.19

EPS basic, restated for Jul-2026 1:10 consolidation (USD)

-71.50-27.50-6.20-7.80-1.90

Weighted avg. basic shares, as reported (K)

3,5033,5694,5215,4537,352

Dividends per share (USD)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023

Gross margin (%)

5.36.22.4

Operating margin (%)

-1,245.6-1,351.0-2,486.0

Net margin, total net loss / revenue (%)

-1,758.6-889.3-1,006.3

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Gain/(loss) on marketable securities (USD K)

-8,032-134-900

Gain on / fair-value change of long-term investments (USD K)

05,5886,43100

Impairment of long-term investments (USD K)

00-77-1,0000

Government subsidies (USD K)

001239280

Change in fair value of warrant liability (USD K)

0000690

Interest income/(expense), net (USD K)

-94147-121-147-96

Balance Sheet — Total assets

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (USD K)

21,90720,86720,64016,13018,691

Cash and cash equivalents (USD K)

8,1311,8832,0058743,453

Restricted cash (USD K)

1303,130000

Current assets (USD K)

12,6887,0682,4769603,593

Current liabilities (USD K)

4,37712,5032,0994,3394,594

Working capital (USD K)

8,311-5,435377-3,379-1,001

Long-term investments (USD K)

4,1579,74516,09915,09915,099

Property and equipment, net (USD K)

3,7312,8251,66400

Intangible assets, net (USD K)

88075314700

Goodwill (USD K)

00000

Short-term debt (USD K)

06,0133,0593,2393,419

Long-term debt (USD K)

0500000

Total debt (USD K)

06,5133,0593,2393,419

Net debt (USD K)

-8,1314,6301,0542,365-34

Total liabilities (USD K)

4,40113,0345,2574,3534,900

Equity attributable to company (USD K)

23,60715,71224,84621,13523,115

Non-controlling interests (USD K)

-6,101-7,879-9,463-9,357-9,371

Total equity (USD K)

17,5067,83315,38311,77713,745

Accumulated deficit (USD K)

-55,538-65,337-68,162-72,430-73,793

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (USD K)

-14,652-12,319-7,724-1,190-1,837

Investing cash flow (USD K)

16,5072,445625590

Financing cash flow (USD K)

2,7816,6254,09204,415

Net change in cash incl. restricted (USD K)

4,636-3,249-3,008-1,1312,579

Dividends paid (USD K)

00000

Share buybacks (USD K)

00000

Financial Ratios (x) and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Current ratio (x)

2.900.571.180.220.78

Debt to total equity (x)

0.000.830.200.280.25

ROIC, operating loss / year-end invested capital (%)

-204.9-140.5-65.2-27.9-13.3

Asset turnover, revenue / year-end assets (x)

0.070.060.0200

Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025

ROE, attributable net loss / avg attributable equity (%)

-49.8-13.9-18.6-6.2

ROA, total net loss / avg total assets (%)

-53.9-20.9-22.6-7.9

Revenue by Region

MetricFY2021FY2022FY2023FY2024FY2025

Hong Kong revenue (USD K)

1,5421,29643100

United States revenue (USD K)

00000

Europe/UK revenue (USD K)

00000

Rest of world revenue (USD K)

00000

Region Margins & Growth (%)

MetricFY2022FY2023FY2024

Hong Kong revenue YoY growth (%)

-15.9-66.7-100.0

Share Price & Returns

DateClose (USD)NotesSource

Jul 22, 2026

8.99

Two days after NIKI debut

MarketChameleon

Aug 21, 2026

8.58—

MarketChameleon

Aug 28, 2026

6.90

Shelf filed same day

StockAnalysis

Sep 4, 2026

6.20

Intraday range 6.05–9.68; volume 4.14M versus ~152K average

Benzinga; Yahoo

Sep 9, 2026

6.01—

Benzinga

Sep 16, 2026

4.77

Used for S-3/A public-float calculation

S-3/A

Sep 18, 2026

4.72

Latest verified close

Benzinga

Valuation Snapshot

MetricValueBasis

Market capitalization

~USD 13.2M

2,793,591 shares × $4.72 (Sep 18, 2026); analyst calculation

Enterprise value (indicative)

~USD 14.8M

Market cap + $3.42M related-party convertible notes (Dec 31, 2025) − $1.83M cash (Jun 30, 2026). Mixed dates; indicative only

P/E

n/m

Losses

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

Zero revenue

P/B (indicative)

~0.57x

Market cap ÷ legacy Aptorum attributable equity of $23.1M (Dec 31, 2025). Excludes DiamiR's post-merger book value and is inflated by the illiquid $15.1M investment

Peer multiples

Not computed.

—

Capital Markets

ItemStatus

Analyst consensus / price targets

None; Benzinga reports no analyst price target

Dividend history and policy

Never paid. No dividend policy; earnings to be retained (S-3/A)

Credit ratings (Moody's / S&P / Fitch)

Not rated

Shelf capacity

$75M S-3, limited by General Instruction I.B.6 to one-third of public float per 12 months while float is below $75M. That is about $1.7M on a ~$5.04M float (analyst calculation from S-3/A)

Equity incentive plan

2026 Incentive Plan (pool size not disclosed in sources reviewed)

Warrants outstanding

Warrants from the Oct 2025 RDO (up to 2,000,000 pre-split at $2.00, i.e. ~200,000 at ~$20.00 post-split; analyst adjustment, terms subject to warrant anti-dilution provisions). Carried as a $306K liability plus $47K temporary equity at Dec 31, 2025

Capital Instruments

InstrumentAmount (Dec 31, 2025)ClassificationMaturity / terms

Convertible notes to a related party

USD 3,418,500

Current

Within 12 months (classified current); interest rate and conversion terms not disclosed in sources reviewed

Amounts due to related parties

USD 79,180

Current

On demand

Bank debt

Nil

—

$3.0M bank loan repaid in FY2023

Analyst Conclusions

Management guidance and consensus

Management guidance: none quantitative. Qualitative priorities are LDT development, expanding testing services, validation collaborations, and partnering the therapeutics (S-3/A; 2026 releases).

Consensus: no sell-side coverage; no consensus estimates exist.

Bull case

  1. A real, regulated revenue engine exists from day one. A CLIA/CAP lab with an NYS-approved APOE test and a signed sponsor agreement (PMR) offers an early, low-capex path to services revenue. Sponsor-driven APOE demand is structural in the anti-amyloid era.

  2. Valuation is a fraction of book and of strategic replacement cost. At ~$13M market cap against $23.1M legacy attributable equity, the market assigns little value to the miRNA platform, the lab or two Phase-1-complete assets (one with orphan designation).

  3. Scientific momentum is building. Two CTAD 2025 abstracts, three AAIC 2026 presentations, a peer-reviewed glioblastoma paper, and a head-to-head biomarker study against PET-confirmed status (AlzLabs) are the kind of data that could attract a partner or acquirer.

Bear case

  1. Survival financing will be highly dilutive. Cash was $1.83M at June 30, 2026 against a $1.55M half-year burn before adding DiamiR's costs. Both entities carry going-concern opinions. The baby-shelf cap (~$1.7M per 12 months on the current float) means repeated small raises, warrant-heavy structures or related-party funding.

  2. Competitive irrelevance risk. The AD blood-test market is coalescing around protein p-Tau217 assays from heavily capitalized players. APOE genotyping is a commodity at Quest and Labcorp. miRNA signatures must clear a high evidentiary bar before payers or clinicians adopt them.

  3. Governance and structure discount. A 51.56% controlling holder, combined Chair/CEO, related-party convertible debt, an opaque $15.1M investment, Hong Kong/PRC regulatory overlays, and a history of failed and completed reverse mergers and two reverse splits in 3.5 years all argue for a persistent discount.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableWhy it matters
First 10-Q/10-K as combined companyFirst disclosure of consolidated cash, burn, DiamiR revenue, goodwill and intangibles
Financing under the $75M shelf (size, price, warrants)Dilution and runway
Nasdaq compliance status (bid price, stockholders' equity)Listing continuity
New services agreements and test-volume disclosuresEvidence of a revenue trajectory
AlzLabs and INB study readoutsPlatform validation; lab throughput
LDT launch for miRNA brain-health signatureTransition from services to proprietary tests
Partnering or out-licensing of SACT-1 or ALS-4Non-dilutive capital; asset value realization
Clarity on the $15.1M long-term investmentAsset quality; potential monetization
First DEF 14ACompensation, committees and ownership transparency
Hong Kong/PRC regulatory developmentsHFCAA/CSRC exposure

Analyst verdict

Niki BioSolutions is not an operating company in the conventional sense yet. It is a recapitalized listed vehicle wrapped around a very small U.S. diagnostics laboratory and a shelf of suspended drug programs. Legacy Aptorum's record over FY2021–FY2025 is one of steady retrenchment. Operating losses fell from $19.2M to $1.8M, but revenue went to zero, headcount went to one, and survival depended on equity issuance, related-party convertible notes and non-cash fair-value gains. The DiamiR merger changes the narrative, not yet the numbers. It brings a CLIA/CAP lab, an NYS-approved APOE test, a nascent sponsor customer base and a differentiated microRNA platform with credible scientific activity in 2025–2026.

The investment question is binary and financing-led. On the positive side, the company is priced at roughly $13M, below the book value carried in legacy Aptorum's last balance sheet, and its regulated lab gives it a services foothold in a growing Alzheimer's testing ecosystem. On the negative side, liquidity is critical: $1.83M of cash at mid-2026, going-concern language at parent and subsidiary, and a baby-shelf constraint that caps registered primary issuance at roughly $1.7M a year at the current float. Most realistic funding paths are therefore dilutive or related-party-dependent. Competitive dynamics are also unforgiving. Protein p-Tau217 tests from well-funded incumbents set the standard against which any miRNA approach must prove incremental value, and APOE genotyping is commoditized.

Governance warrants a discount: a controlling holder, combined Chair/CEO, an opaque $15.1M investment, and residual Hong Kong regulatory exposure. Verdict: speculative, high-risk; suitable only as a small, event-driven position. The key monitorables are the first consolidated 10-Q, the terms of the next financing, disclosed test volumes or revenue from DiamiR's services, and any partnering of SACT-1 or ALS-4. Absent a non-dilutive partnership or clear services-revenue traction within 12 months, the base case is continued dilution and listing-compliance pressure.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NamePositionBackground (as available)Tenure notes

Ian Huen

Chairman; signs filings as Chief Executive Officer

Founder and long-time controlling shareholder of Aptorum. 100% owner of Jurchen Investment Corporation, which owns 76.8% of Aeneas Limited (Aeneas Group)

Director since Aptorum's formation; CEO by 2024. Inconsistency: the FY2025 20-F definitions describe him as "former CEO," while the Jul 2026 8-K and Sep 2026 S-3/A identify him as CEO

Kira S. Sheinerman, Ph.D.

Director

DiamiR co-founder; reported 51.56% beneficial owner of Niki common stock

Joined at merger close

Justin Wu

Independent Director

—

Carried over from Aptorum board

Douglas Arner

Independent Director

—

Carried over from Aptorum board

Laura A. Philips

Independent Director

—

Joined at merger close

Alidad Mireskandari, Ph.D.

Board Observer; President & COO

Former CEO of DiamiR (quoted as such in the Jun 22, 2026 release). Presented the company at the H.C. Wainwright conference on Sep 14, 2026

Observer since merger close

Executive Leadership Team

NameTitleNotes

Ian Huen

Chief Executive Officer (per S-3/A agent for service)

Also Chairman, which means CEO and Chair roles are not separated

Alidad Mireskandari, Ph.D.

President & Chief Operating Officer

Operating lead for the DiamiR business

Darren Lui

Former CEO & Executive Director (FY2022 period)

Departure date not confirmed in sources reviewed

Major Shareholders

HolderStakeSource / notes

Kira S. Sheinerman

51.56% beneficial ownership of common stock

BriefGlance, Sep 8, 2026, citing company filings

Ian Huen / Jurchen Investment Corporation

Not precisely disclosed in sources reviewed. Pre-merger Jurchen controlled Aptorum through Class B shares (1,796,934 pre-split). Each Class B share converted into one common share plus one Series A Preferred share, so Jurchen's post-merger common stake is at least ~179,693 shares (~6.4%) if Jurchen held all Class B. Unconfirmed

Form 8-K; FY2025 20-F

All affiliates combined

~62% (2,793,591 total common − 1,056,729 non-affiliate shares = ~1,736,862 affiliate shares)

Analyst calculation from S-3/A and 8-K

Public float

~1.06M shares (~38%)

S-3/A

Top-10 institutional holders

Not publicly disclosed in sources reviewed. Given a ~$5M non-affiliate float, institutional ownership is likely de minimis

—

Series A Preferred (179,693 shares)

Held by former Aptorum Class B holders. Non-voting, non-convertible, non-redeemable. Entitled to a share of sale or liquidation proceeds under the merger's 70/30 allocation

Form 8-K (Series A COD)

Board & Management Changes

DateChange

Oct 9, 2025

Aptorum announced it would expand its board and management with executives in connection with the DiamiR merger

Jul 20, 2026

New board seated (Sheinerman and Philips added; Mireskandari as observer). Voting and Support Agreement and Stockholder Agreement executed. The final Stockholder Agreement lowered the ownership threshold required to be a signatory

Sep 2026

Mireskandari publicly titled President & COO (H.C. Wainwright conference release, Sep 8, 2026)

Competitive Landscape

Competitors by Segment

Business lineCompetitorRelevant offeringRelative positioning vs Niki

Blood-based Alzheimer's diagnostics

C2N Diagnostics (private)

PrecivityAD2 (plasma p-Tau217/Aβ42/40)

Commercial leader in U.S. specialty AD blood testing; far ahead on validation and payer engagement

Blood-based Alzheimer's diagnostics

Quanterix (Nasdaq: QTRX)

Simoa p-Tau217 and LucentAD assays; NfL

Platform and assay vendor with an installed base.

Blood-based Alzheimer's diagnostics

Fujirebio (H.U. Group)

—

Regulated IVD with automation scale

Blood-based Alzheimer's diagnostics

Roche Diagnostics

Elecsys plasma p-Tau assays

Global IVD incumbent

Reference lab testing (AD panels, APOE)

Quest Diagnostics (NYSE: DGX)

AD-Detect panels; APOE genotyping

National reference-lab scale; APOE is commoditized there

Reference lab testing (AD panels, APOE)

Labcorp (NYSE: LH)

ATN profile; APOE genotyping

National scale; payer contracts

AD biomarker technology

ALZpath (private)

p-Tau217 antibody/assay technology

Technology licensor to labs

microRNA diagnostics

MiRXES (Singapore)

miRNA-based cancer screening tests

More advanced commercial miRNA franchise

microRNA diagnostics

Hummingbird Diagnostics (Germany)

Blood small-RNA signature diagnostics

Direct technology peer, private

Neuroblastoma therapeutics (vs SACT-1)

United Therapeutics (Unituxin, dinutuximab)

Approved anti-GD2 antibody

Standard-of-care incumbent

Neuroblastoma therapeutics (vs SACT-1)

Y-mAbs Therapeutics (Danyelza, naxitamab)

Approved anti-GD2 antibody

Approved competitor

Neuroblastoma therapeutics (vs SACT-1)

US WorldMeds (Iwilfin, eflornithine)

Approved maintenance therapy (FDA 2023)

Approved oral therapy in an adjacent setting

MRSA / anti-infectives (vs ALS-4)

Generic and branded anti-MRSA antibiotics (vancomycin, linezolid, daptomycin)

Approved antibiotics

Entrenched, low-cost standard of care

Peer Comparison FY2025

MetricNiki BioSolutions (legacy FY2025)Quanterix (FY2024)Quest Diagnostics (FY2024)Labcorp (FY2024)

Revenue

USD 0

~USD 137M

~USD 9.9B

~USD 13.0B

Revenue growth

n/m (−100% vs FY2023)

———

Operating margin

n/m (operating loss USD 1.8M)

———

R&D intensity

n/m (R&D USD 0.35M)

———

Company Snapshot

1

Employees

2010

Founded

NJ, US

Headquarters

SWOT Analysis

Strengths

  • Regulated lab infrastructure: CLIA-certified, CAP-accredited laboratory (S-3/A, Sep 2026)
  • State-approved test: NYS approval of the DiamiR APOE genotyping test (Aug 21, 2025)
  • Active scientific output: 2 CTAD 2025 abstracts; 3 AAIC 2026 presentations; UPenn Diagnostics publication (Mar 2026)
  • Commercial and partner traction: PMR APOE services agreement (Jul 23, 2026); INB (Feb 2026) and AlzLabs (Jun 2026) collaborations
  • Therapeutic optionality: SACT-1 and ALS-4 completed Phase 1 with positive results (2022); SACT-1 has orphan designation and an agreed 505(b)(2) pathway (FY2025 20-F)
  • Very low fixed cost base: FY2025 total operating expenses of $1.82M versus $20.75M in FY2021 (Form 20-F)
  • Book equity anchored by investments: $15.1M long-term investments; attributable equity of $23.1M (FY2025)

Weaknesses

  • No revenue: Revenue nil in FY2024–FY2025 and H1 2026
  • Going-concern doubt at both parent and subsidiary: Aptorum FY2025 20-F; DiamiR audit for FY ended May 31, 2026 (S-3/A)
  • Thin liquidity: Cash $1.83M and working capital −$2.48M at Jun 30, 2026 (company filing via BriefGlance)
  • Related-party leverage: $3.42M convertible notes owed to a related party, all current (FY2025 balance sheet)
  • Minimal organization: 1 employee at Dec 31, 2025 (legacy); post-merger headcount undisclosed
  • Opaque principal asset: $15.1M long-term investment (81% of assets) with investee not described in sources reviewed; $1.0M impairment in FY2024
  • Weak governance optics: Combined Chair/CEO; controlled company; 3 of 5 directors independent; inconsistent CEO titling across filings

Opportunities

  • AD blood-testing demand: Anti-amyloid therapy era; AlzLabs study benchmarks miRNA against p-Tau217, Aβ42/40 and NfL
  • APOE testing demand from trials and therapy safety screening: PMR agreement shows sponsor demand
  • Lab throughput expansion via automation: INB G8 validation (Feb 2026)
  • Out-licensing or partnering of SACT-1/ALS-4: Company actively seeking collaborators (FY2025 20-F)
  • Capital access through domestic-issuer status: $75M S-3 shelf; Delaware domicile; investor conferences (Sep 2026)
  • Lighter U.S. LDT regulatory burden: FDA LDT rule vacated (Mar 2025; recalled) supports DiamiR's LDT-first plan
  • Oncology extension of the miRNA platform: UPenn glioblastoma study (Mar 2026)

Threats

  • Dilution: Baby-shelf cap of one-third of a ~$5.0M public float ≈ $1.7M per 12 months under General Instruction I.B.6 (S-3/A). That forces small, frequent, dilutive raises or more expensive structures
  • Nasdaq listing risk: Bid-price notices in Apr 2025 and Mar 2026; stockholders' equity and MVPHS issues in 2023; 1:10 reverse splits in Jan 2023 and Jul 2026
  • China/Hong Kong regulatory overlay: S-3/A HFCAA/CSRC/CAC risk language; SEC comments required expanded HK risk disclosure (Sep 2026)
  • Superior-funded competitors: C2N, Quanterix, Fujirebio, Roche, Quest, Labcorp
  • Share-price collapse: Stock fell from ~$8.99 (Jul 22) to $4.72 (Sep 18, 2026); a decline of more than 67% over the past year was reported by BriefGlance
  • Execution and integration risk: Cross-border combination of a Hong Kong-legacy holding company with a U.S. lab, with minimal staff

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 15–16, 2025Nasdaq minimum bid price deficiency notice; compliance deadline Oct 14, 2025Listing risk
Apr 30, 2025FY2024 Form 20-F filedAnnual disclosure; going concern
Jul 14, 2025DiamiR merger agreement signed, with MSA and IP licenseTransformational
Jul 16, 2025Merger publicly announcedStrategic pivot to diagnostics
Jul 22, 2025Form 6-K with merger agreement and ancillary agreementsTransparency on terms
Aug 4, 2025Regained bid-price complianceListing relief
Aug 21, 2025NYS approval of DiamiR APOE genotyping testFirst regulatory asset of the combined story
Sep 5, 2025Aptorum and DiamiR to present at H.C. Wainwright 27th conferenceInvestor outreach
~Sep 2025H1 2025 interim results: net loss $449,295 (H1 2024: $2,658,887)Cost containment
Oct 6, 2025Form S-4 filedMerger process
Oct 9, 2025Board and management expansion announcedGovernance build-out
Oct 10, 2025Up to $6M RDO ($2M upfront plus warrants)Funding of merger expenses and working capital
Nov 19, 2025Two abstracts accepted at CTAD 2025Scientific validation
Dec 2, 2025First amendment to the Management Services AgreementBridge economics with DiamiR
Feb 2, 2026INB APOE automation collaborationLab capacity
Mar 6, 2026Second Nasdaq bid price deficiency noticeListing risk recurs
Mar 10, 2026UPenn glioblastoma miRNA study publication; second MSA amendmentPlatform breadth
Mar 27, 2026FY2025 Form 20-F: net loss $1.38M; negative working capital $1.0M; going-concern doubtFinancial fragility
May 13, 2026S-4 declared effectivePath to vote
Jun 9, 2026Shareholders approve merger and 1-for-10 consolidationClosing condition met
Jun 22, 2026AlzLabs collaboration; third MSA amendmentClinical validation
Jul 2026Three AAIC 2026 presentationsScientific visibility
Jul 16, 2026Closing date set for Jul 20; NIKI ticker and new CUSIP announcedLogistics
Jul 20, 2026Domestication, reverse split, merger close, rename, new board, 2026 Incentive PlanNew entity
Jul 23, 2026PMR APOE testing services agreementFirst post-close commercial deal
Aug 21, 2026Form 8-K/A with acquired-business and pro forma financialsFinancial transparency
Aug 28, 2026$75M universal shelf (S-3) filedDilution overhang; financing capacity
Sep 4, 2026Intraday spike to $9.68 on 4.14M shares (average ~152K), then close at $6.20Extreme volatility
Sep 8 / Sep 14, 2026H.C. Wainwright 28th conference announced, then presentation by MireskandariCapital-raising groundwork
~Sep 2026H1 2026 interim figures: net loss $1.31M, OCF −$1.55M, cash $1.83M, WC −$2.48M, going-concern languageLiquidity alarm
Sep 18, 2026S-3 Pre-Effective Amendment No. 2 responding to SEC comments on incorporation by reference and Hong Kong risk disclosureRegulatory scrutiny of the HK nexus
Sep 25 / Sep 29–30, 2026Lytham Partners Fall 2026 Investor ConferenceInvestor outreach

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Total operating expenses incl. cost of services fell from USD 20.7 Mn in FY2021 to USD 1.8 Mn in FY2025.
Niki BioSolutions Inc. — Income Statement: Revenue & Gross Profit
Series (USD Mn)FY2021FY2022FY2023FY2024FY2025
Total operating expenses incl. cost of services20.718.811.23.91.8
Revenue1.51.30.400
Cost of healthcare services1.51.20.400
Gross profit0.10.1000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Niki BioSolutions, Form S-3/A (Pre-Effective Amendment No. 2), Sep 18, 2026 (sec.gov)
  2. Niki BioSolutions, Form 8-K (merger completion), Jul 20, 2026 (aptorumgroup.gcs-web.com)
  3. Niki BioSolutions, Form 8-K/A (event Aug 21, 2026) (ir.aptorumgroup.com)
  4. Aptorum Group, Form 20-F FY2025 (sec.gov)
  5. Aptorum Group, FY2025 20-F XBRL statements (R2, R3, R4, R5) (sec.gov)
  6. Aptorum Group, FY2023 20-F XBRL balance sheet (sec.gov)
  7. Aptorum Group, FY2022 20-F XBRL statements (sec.gov)
  8. Aptorum Group, Form 20-F FY2023 (cash flows) (sec.gov)
  9. Aptorum Group, Form 20-F FY2022 (sec.gov)
  10. Aptorum Group, Form 20-F FY2024 (sec.gov)
  11. Aptorum $3.0M RDO release (Form 6-K), Jan 2, 2025 (sec.gov)
  12. Aptorum up to $6M RDO release (Form 6-K), Oct 2025 (sec.gov)
  13. Aptorum Nasdaq bid price notice (Form 6-K), Apr 16, 2025 (sec.gov)
  14. Aptorum H1 2024 results and YOOV termination (Business Wire), Dec 20, 2024 (businesswire.com)
  15. Aptorum 1-for-10 reverse split (Business Wire), Jan 2023 (businesswire.com)
  16. Aptorum Nasdaq MVPHS notice (Business Wire), Feb 10, 2023 (businesswire.com)
  17. Aptorum FY2022 results (Business Wire), Apr 27, 2023 (businesswire.com)
  18. Aptorum FY2023 results (Business Wire), Apr 24, 2024 (businesswire.com)
  19. Merger update press release (Finviz/GlobeNewswire), Jul 16, 2026 (finviz.com)
  20. AlzLabs collaboration release, Jun 22, 2026 (chartmill.com)
  21. DiamiR–INB collaboration (GenomeWeb/360Dx), Feb 2026 (360dx.com)
  22. H.C. Wainwright conference release, Sep 8, 2026 (finviz.com)
  23. Lytham Partners conference release, Sep 25, 2026 (finviz.com)
  24. BriefGlance, "Niki BioSolutions: A High-Stakes Pitch for Survival," Sep 8, 2026 (briefglance.com)
  25. Panabee, merger completion summary (panabee.com)
  26. StockTitan NIKI news (PMR agreement) (stocktitan.net)
  27. FinancialContent publisher pages (Aptorum and Niki release chronology) (markets.financialcontent.com)
  28. StockAnalysis NIKI profile and employees (stockanalysis.com)
  29. Benzinga NIKI quote (benzinga.com)
  30. Yahoo Finance NIKI quote (finance.yahoo.com)
  31. MarketChameleon NIKI summary (marketchameleon.com)
  32. Weiss Ratings NIKI profile (weissratings.com)
  33. Simply Wall St NIKI (simplywall.st)
  34. AlphaQuery NIKI fundamentals (alphaquery.com)
  35. Insider Monkey via Tiger, YOOV termination context, Dec 31, 2024 (itiger.com)
  36. TipRanks/Barchart, H1 2025 interim results (barchart.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.